Cover Image
市場調查報告書

腎上腺皮質刺激荷爾蒙受體:開發中產品分析

Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 359405
出版日期 內容資訊 英文 49 Pages
訂單完成後即時交付
價格
Back to Top
腎上腺皮質刺激荷爾蒙受體:開發中產品分析 Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Pipeline Review, H2 2017
出版日期: 2017年10月31日 內容資訊: 英文 49 Pages
簡介

本報告提供腎上腺皮質刺激荷爾蒙受體的開發情形相關調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息與新聞稿等資訊。

簡介

  • 調查範圍

腎上腺皮質刺激荷爾蒙受體概要

治療藥的開發

腎上腺皮質刺激荷爾蒙受體:開發中的產品 - 各開發階段

腎上腺皮質刺激荷爾蒙受體:開發中的產品 - 各治療範圍

腎上腺皮質刺激荷爾蒙受體開發中的產品 - 各適應症

腎上腺皮質刺激荷爾蒙受體:開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

腎上腺皮質刺激荷爾蒙受體:企業開發中的產品

腎上腺皮質刺激荷爾蒙受體:治療藥的評估

  • 單劑產品
  • 各產品
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

腎上腺皮質刺激荷爾蒙受體的治療藥開發企業

  • Alder Biopharmaceuticals Inc.
  • Ipsen S.A.
  • Mallinckrodt Plc
  • Pfizer Inc.
  • Retrophin Inc.
  • XOMA Corporation

腎上腺皮質刺激荷爾蒙受體:藥物簡介

腎上腺皮質刺激荷爾蒙受體:暫停中的計劃

腎上腺皮質刺激荷爾蒙受體:開發中止的產品

腎上腺皮質刺激荷爾蒙受體:主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1101TDB

Summary:

According to the recently published report 'Adrenocorticotropic Hormone Receptor - Pipeline Review, H2 2017'; Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) pipeline Target constitutes close to 6 molecules. Out of which approximately 6 molecules are developed by Companies.

Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - The adrenocorticotropic hormone receptor also known as the melanocortin receptor 2 is a type of melanocortin receptor (type 2) which is specific for ACTH. ACTH receptor is found in the zona fasciculata of adrenal cortex. Binding of the receptor by ACTH stimulates the production of cortisol.

The report 'Adrenocorticotropic Hormone Receptor - Pipeline Review, H2 2017' outlays comprehensive information on the Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Preclinical and Discovery stages are 2, 3 and 1 respectively. Report covers products from therapy areas Central Nervous System, Hormonal Disorders, Metabolic Disorders, Genito Urinary System And Sex Hormones and Musculoskeletal Disorders which include indications Infantile Spasm (West Syndrome), Pituitary ACTH Hypersecretion (Cushing Disease), Acromegaly, Amyotrophic Lateral Sclerosis, Congenital Adrenal Hyperplasia (Adrenogenital Syndrome), Gouty Arthritis (Gout), Multiple Sclerosis and Nephrotic Syndrome.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R)
  • The report reviews Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Overview
    • Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
  • Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Companies Involved in Therapeutics Development
    • Ipsen SA
    • MallInckrodt Plc
    • Pfizer Inc
    • Retrophin Inc
  • Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Drug Profiles
    • AQB-565 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BIM-23B065 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • corticotropin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • corticotropin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cosyntropin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize Melanocortin Receptor 2 for ACTH-dependent Cushing's syndrome and Congenital Adrenal Hyperplasia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Dormant Products
  • Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Discontinued Products
  • Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Product Development Milestones
    • Featured News & Press Releases
      • Oct 09, 2017: Mallinckrodt Statement on October 7, 2017, CHEST Journal Article
      • Oct 09, 2017: Mallinckrodt Will Conduct Phase 4 Trial of H.P. Acthar Gel (Repository Corticotropin Injection) for Symptomatic Sarcoidosis
      • Sep 12, 2017: Open Letter to Mallinckrodt Employees, Customers and Patients Reinforcing Important Facts Related to H.P. Acthar Gel and Other Matters
      • Jul 31, 2017: Summary Review of Clinical and Economic Data on H.P. Acthar Gel Published in Advances in Therapy
      • Jul 25, 2017: Mallinckrodt Posts Data From Legacy H.P. Acthar Gel (Repository Corticotropin Injection) Pilot Study To clinicaltrials.gov
      • Jun 26, 2017: MNK H.P. Acthar Gel DN Trial Results Alert
      • Jun 22, 2017: Mallinckrodt Statement on H.P. Acthar Gel Update
      • Jun 14, 2017: Mallinckrodt Enrolls First Patient in Phase 2B Trial of H.P. Acthar Gel (Repository Corticotropin Injection) for Amyotrophic Lateral Sclerosis
      • Jun 06, 2017: Mallinckrodt Updates Facts Refuting Short-Seller Claims
      • May 25, 2017: Mallinckrodt Highlights First Patients in Company-Sponsored Prospective Observational Registry on the Use of H.P. Acthar Gel (Repository Corticotropin Injection) Following Acute Multiple Sclerosis Relapse
      • May 23, 2017: First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar Gel (Repository Corticotropin Injection) for Multiple Sclerosis Relapse
      • Apr 28, 2017: Mallinckrodt Data from New Company-Sponsored Studies Presented at American Academy of Neurology 69th Annual Meeting
      • Feb 21, 2017: Mallinckrodt Statement on H.P. Acthar Gel (Repository Corticotropin Injection)
      • Nov 21, 2016: Mallinckrodt Will Initiate Company-Sponsored Clinical Trial of H.P. Acthar Gel in Treatment of Amyotropic Lateral Sclerosis
      • Nov 17, 2016: Study Addresses Possible Impact of H.P. Acthar Gel on Use of Corticosteroids Among Patients with Rheumatoid Arthritis, Lupus, and Dermatomyositis/Polymyositis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indication, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by Ipsen SA, H2 2017
  • Pipeline by MallInckrodt Plc, H2 2017
  • Pipeline by Pfizer Inc, H2 2017
  • Pipeline by Retrophin Inc, H2 2017
  • Dormant Projects, H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indications, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top